Navigation Links
Cardiac Science Named to Deloitte's Technology Fast 50 for Washington State
Date:9/28/2007

in 2002 and $5,000,000 in 2006, be headquartered in North America, and be a company that owns proprietary technology or proprietary intellectual property that contributes to a significant portion of the company's operating revenues; or devotes a significant proportion of revenues to the research and development of technology. Using other companies' technology or intellectual property in a unique way does not qualify.

Companies from the 16 regional Technology Fast 50 programs in the United States and Canada are automatically entered in Deloitte's Technology Fast 500 program, which ranks North America's top 500 fastest growing technology, media, telecommunications and life sciences companies. For more information on Deloitte's Technology Fast 50 or Technology Fast 500 programs, visit http://www.fast500.com.

This year's Washington State Technology Fast 50 program is co-presented by Deloitte & Touche USA LLP and Perkins Coie, Citibank, AH&T Insurance and the Puget Sound Business Journal.

About Cardiac Science Corporation

Cardiac Science is truly at the heart of saving lives. The Company develops, manufactures, and markets a family of advanced diagnostic and therapeutic cardiology devices and systems, including AEDs, electrocardiographs, stress test systems, Holter monitoring systems, hospital defibrillators, cardiac rehabilitation telemetry systems, patient monitor -- defibrillators and cardiology data management systems. Cardiac Science also sells a variety of related products and consumables, and provides a comprehensive portfolio of training, maintenance and support services. The Company is the successor to various entities that have owned and operated cardiology-related businesses that sold products under the trusted brand names Burdick(R), Powerheart(R), and Quinton(R). Cardiac Science is headquartered in Bothell, WA, and also has operations in Lake Forest, California; Deerfield, Wisconsin;
'/>"/>

SOURCE Cardiac Science Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Thyroid hormone treatment hastens recovery after cardiac surgery
2. Gene HPA-2 Met linked to cardiac arrest
3. Defibrillators In Public Places Will Help Cardiac Patients
4. Supplement helps cardiac surgery
5. Cardiac diseases develop early
6. Latest device for cardiac revival under test
7. Bone marrow stem cells may help repair cardiac tissues
8. Heart problems detected better with a Cardiac MRI
9. Cardiac events better treated with intense cholesterol-lowering regime
10. Sudden Cardiac Death due to inherited Heart Disease
11. Vasopressin Found To Boost Survival In Sudden Cardiac arrest
Post Your Comments:
*Name:
*Comment:
*Email:
Other Medicine News:Health News:New Asia Pacific Statistics Reveal an Alarming Incidence of HIV in MSM 2Health News:New Asia Pacific Statistics Reveal an Alarming Incidence of HIV in MSM 3Health News:New Asia Pacific Statistics Reveal an Alarming Incidence of HIV in MSM 4Health News:New Asia Pacific Statistics Reveal an Alarming Incidence of HIV in MSM 5Health News:New Asia Pacific Statistics Reveal an Alarming Incidence of HIV in MSM 6Health News:EpiCept Corporation to Present at the BMO Capital Markets 2007 Focus on Healthcare Conference 2Health News:EpiCept Corporation to Present at the BMO Capital Markets 2007 Focus on Healthcare Conference 3Health News:Hanger Orthopedic Group, Inc. Announces Three Acquisitions Totaling Over $3.5 Million of Annual Net Revenue 2Health News:Global Summit on AIDS and the Church Begins Today and Concludes With Youth Summit on World AIDS Day: 2Health News:Global Summit on AIDS and the Church Begins Today and Concludes With Youth Summit on World AIDS Day: 3Health News:Rise in CT Scans Poses Cancer Risk 2Health News:Rise in CT Scans Poses Cancer Risk 3Health News:Genetic differences point to ethnic and racial disparities in colorectal cancer risk 2Health News:Genetic differences point to ethnic and racial disparities in colorectal cancer risk 3